AveXis Plans a May Start for Phase 3 European Trial of Its SMA Type 1 Gene Therapy
News
AveXis’ expects to start a Phase 3 clinical trial of its spinal muscular atrophy (SMA) gene therapy AVXS-101 in Europe in May. The STR1VE-EU trial (NCT03461289) is expected to include up to ... Read more